Search Results

Your search for Robert Coleman, MD, FRCP,Robert Coleman, MD, FRCP matches 2 pages

Showing 1 - 2

By Matthew Stenger / January 2020

D-CARE Trial: Adjuvant Denosumab for Patients With Early Breast Cancer

As reported in The Lancet Oncology by Robert Coleman, MD, FRCP, and colleagues, the phase III D-CARE trial has shown no benefit of adjuvant therapy with the RANKL inhibitor denosumab vs placebo in improving bone metastasis–free survival in women with moderate- to high-risk early breast cancer....

breast cancer

symptom management

By Robert Coleman, MD, FRCP / May 25, 2017

OPTIMIZE-2 Trial Offers Reassuring Data on Deescalation of Bisphosphonate Therapy for Breast Cancer–Related Bone Metastases

Bisphosphonates were first synthesized more than a century ago, with their initial usage restricted to a range of industrial processes until their potential clinical relevance was appreciated in the late 1960s.1 Then, following development for the treatment of osteoporosis and Paget’s disease of...

Apr

Today In Oncology

Search Results

Your search for Robert Coleman, MD, FRCP,Robert Coleman, MD, FRCP matches 2 pages

D-CARE Trial: Adjuvant Denosumab for Patients With Early Breast Cancer

OPTIMIZE-2 Trial Offers Reassuring Data on Deescalation of Bisphosphonate Therapy for Breast Cancer–Related Bone Metastases

Adjuvant Pembrolizumab in Renal Cell Carcinoma: Overall Survival in KEYNOTE-564

Combined ICI and VEGF Inhibitor Trials in Cancer Cardiovascular Eligibility Criteria and Adverse Event Reporting

Risk of T-Cell and Second Primary Malignant Neoplasms After CAR T-Cell Therapy

Lack of Research Focused on Older Adults With Cancer May Be Contributing to Disparities in Care

Breast Cancer Survivors: Relationship Satisfaction and Emotional and Physical Well-Being